Nasdaq GlobeNewswire

Integra LifeSciences to Hold First International Tissue Technologies Symposium on June 16 - 17, 2016 in Lisbon, Portugal

Del

PLAINSBORO, N.J., 2016-06-16 09:00 CEST (GLOBE NEWSWIRE) --

Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it is holding its first International Symposium on Tissue Technologies in Lisbon, Portugal, June 16 - 17, 2016.

This event-packed, two-day medical training symposium will bring together over 100 surgeons from Europe, the Middle East and the United States.  The sessions will offer an overview of surgical techniques used in various medical fields, such as dermal reconstruction and regeneration, and plastic and reconstructive procedures, which will be presented by a faculty of world-renowned surgeons.

“As a world leader in Tissue Technologies, Integra is very pleased to offer this training and educational symposium, which will bring together some of the world’s leading plastic and reconstructive surgeons with Integra’s regenerative technology solutions,” said Stephane Corp, Integra’s Vice President, Orthopedics & Tissue Technologies, EMEA .  “Our vision is to provide soft tissue repair technologies that improve patients’ lives, and we are proud to host an event where attendees can share best practices and techniques.  We look forward to working with the surgeons around the globe who share that vision to further research in regenerative products and techniques.”

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2015 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Company

Investors
Angela Steinway                                              
609-936-2268                                                                    
angela.steinway@integralife.com

Michael Beaulieu
609-750-2827
michael.beaulieu@integralife.com

Media – United States
Gianna Sabella
609-775-8553
gianna.sabella@integralife.com

Media – Europe
Marie-Anne Girel
+33 437 475 970
marie-anne.girel@integralife.com

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL(TM) Test for Hodgkin's Lymphoma20.2.2018 14:00Pressemelding

3D Signatures Inc. / 3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL(TM) Test for Hodgkin's Lymphoma . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- 3D Signa­­­­­­tures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HLTM, 3DS' test in development for Hodgkin's lymphoma (HL), shows that the Company's TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months. Telo-HLTM is intended to provide clinicians with the first biomarker to identify the 15% - 20% of new HL patients who will likely fail standard chemot

Cisco Leadership In Automation Continues With New Network Automation Portfolio for Service Providers20.2.2018 14:00Pressemelding

Company launches industry's most comprehensive closed-loop multi-vendor, multi-domain automation solution SAN JOSE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Cisco today introduced its new Cisco Crosswork Network Automation software portfolio to improve how global service providers run their large-scale networks. The solutions are designed to work together to offer greater network visibility at scale (mass awareness), data-driven insights (augmented intelligence) and outcome-based automation (proactive control). With 27 billion devices and connections1 expected to be running on service provider networks by 2021, the pressure is on for industry adoption of complete lifecycle network automation and intent-based networking to help networks predict change and react in near real time. Traditional operations staff will not be able to keep up with adding nearly 10 percent more devices every year without changing how they work. When Cisco automation is utilized, typical results include a 70 pe

Crown Bioscience Inc.: CAR T-Cell Therapy Platform20.2.2018 14:00Pressemelding

Bioluminescent Imaging Capabilities Accelerate Robust CAR T-Cell Therapy SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities. CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics. CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination. The remarkable efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL). CrownBio, a leader in the field of preclinical immuno

Standard Lithium Provides California Lithium Exploration Update20.2.2018 11:30Pressemelding

VANCOUVER, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) is pleased to provide an update of the exploration program that is in full swing at the Company's California Lithium Properties. The Company and their drilling contractors have now completed six exploration boreholes across the Bristol Dry Lake Project area, and three of the exploration holes have had temporary sampling casing installed so that high quality lithium brine samples can be collected from the extensive lithium brine-bearing aquifers. The temporary PVC casing also allows for down-hole geophysics to be completed to collect additional geological and hydrogeological data. Drilling of an observation well is currently ongoing, and once completed, will allow for robust pumping tests to be performed at the Project. An additional exploration well and observation well are already permitted, and the Company is awaiting final con

Infomedia goes global with acquisition of Opoint Technology20.2.2018 10:11Pressemelding

COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The Copenhagen based, Nordic media intelligence company, Infomedia acquires Norwegian Opoint Technology from M-brain. The transfer includes Opoint's leading global web-crawling technology for online media, the business of web-crawling services for +70 international media monitors and key personnel in Oslo and Chennai. Continued international growth in insights, global content and social media Over the last couple of years, Infomedia had begun a journey towards becoming a Nordic player. The company invested heavily in new technology, data science, insight products and services and new partnerships. "We transformed Infomedia from a 'traditional' media monitor to becoming a full-scale media intelligence company with strong insights capabilities and leading solutions within all aspects of the media space, including print, online, broadcast and social media," says Infomedia's CEO, Thomas Vejlemand. He continues; "The acquisition marks y

SoftServe and Adjoint Deliver the Future of Blockchain in FinTech20.2.2018 07:00Pressemelding

New Partnership to Bring Financial Sector Unmatched Security and Scalability for Mission Critical Blockchain Applications LONDON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital consulting company, today announced its partnership with Adjoint, a developer of distributed ledger technology to accelerate automation through smart contracts and improve transactional privacy and security through blockchain in the financial and commodities industries. Adjoint's Uplink is an open source platform designed to enable enterprises in the financial sector, from banking and capital markets, to insurance, asset management, and commodities trading; to quickly deploy, maintain, verify and execute smart contracts globally on a private, permissioned distributed ledger. SoftServe will work with Adjoint to specifically help customers assimilate and on-board the Uplink platform effectively. SoftServe will tap into its deep technical expertise in blockchain, user experience and design, and go-t

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom